About: Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach
Creator	Kamthania, Mohit Sharma, Nishi Srivastava, Sukrit Saxena, Ajay
Source	Medline; PMC
abstract	BACKGROUND: Middle East respiratory syndrome (MERS) is caused by MERS coronavirus (MERS-CoV). Thus far, MERS outbreaks have been reported from Saudi Arabia (2013 and 2014) and South Korea (2015). No specific vaccine has yet been reported against MERS. PURPOSE: To address the urgent need for an MERS vaccine, in the present study, we have designed two multi-epitope vaccines (MEVs) against MERS utilizing several in silico methods and tools. METHODS: The design of both the multi-epitope vaccines (MEVs) are composed of cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) epitopes, screened form thirteen different proteins of MERS-CoV. Both the MEVs also carry potential B-cell linear epitope regions, B-cell discontinuous epitopes as well as interferon-γ-inducing epitopes. Human β-defensin-2 and β-defensin-3 were used as adjuvants to enhance the immune response of MEVs. To design the MEVs, short peptide molecular linkers were utilized to link screened most potential CTL epitopes, HTL epitopes and the adjuvants. Tertiary models for both the MEVs were generated, refined, and further studied for their molecular interaction with toll-like receptor 3. The cDNAs of both MEVs were generated and analyzed in silico for their expression in a mammalian host cell line (human). RESULTS: Screened CTL and HTL epitopes were found to have high propensity for stable molecular interaction with HLA alleles molecules. CTL epitopes were also found to have favorable molecular interaction within the cavity of transporter associated with antigen processing. The selected CTL and HTL epitopes jointly cover upto 94.0% of worldwide human population. Both the CTL and HTL MEVs molecular models have shown to have stable binding and complex formation propensity with toll-like receptor 3. The cDNA analysis of both the MEVs have shown high expression tendency in mammalian host cell line (human). CONCLUSION: After multistage in silico analysis, both the MEVs are predicted to elicit humoral as well as cell mediated immune response. Epitopes of the designed MEVs are predicted to cover large human population worldwide. Hence both the designed MEVs could be tried in vivo as potential vaccine candidates against MERS.
has issue date	2018-11-21(xsd:dateTime)
bibo:doi	10.2147/idr.s175114
bibo:pmid	30538505
has license	cc-by-nc
sha1sum (hex)	ed94f0bd0fe17c099f8cdff4bf9edbbd29ebf41f
schema:url	https://doi.org/10.2147/idr.s175114
resource representing a document's title	Structural basis of development of multi-epitope vaccine against Middle East respiratory syndrome using in silico approach
has PubMed Central identifier	PMC6254671
has PubMed identifier	30538505
schema:publication	Infect Drug Resist
resource representing a document's body	covid:ed94f0bd0fe17c099f8cdff4bf9edbbd29ebf41f#body_text
is schema:about of	named entity 'HTL' named entity 'VACCINE' named entity 'MERS-COV' named entity 'ANALYSIS' named entity 'RESULTS' named entity 'DESIGN' named entity 'COULD BE' named entity 'USED' named entity 'IN SILICO METHODS' named entity 'SUBMIT' named entity 'TERTIARY' named entity 'HUMAN' named entity 'SHORT' named entity 'B-CELL' named entity 'HLA' named entity 'PURPOSE' named entity 'CDNA' named entity 'POTENTIAL' named entity 'CAVITY' named entity 'URGENT' named entity 'HAVE' named entity 'CTL' named entity 'GENERATED' named entity 'MERS VACCINE' named entity 'REGIONS' named entity 'LINEAR' named entity 'ADDRESS' named entity 'HUMAN POPULATION' named entity 'COVER' named entity 'HELPER T LYMPHOCYTE' named entity 'EXPRESSION' named entity 'HTL' named entity 'Screened' named entity 'cover' named entity 'human population' named entity 'complex formation' named entity 'predicted' named entity 'host' named entity 'epitopes' named entity 'Drug' named entity 'PROTEINS' named entity 'EPITOPE' named entity 'CARRY' named entity 'COMPOSED OF' named entity 'EPITOPES' named entity 'IN SILICO' named entity 'MAMMALIAN' named entity 'MULTI' named entity 'IN VIVO' named entity 'ENHANCE' named entity 'REPORTED' named entity 'MANUSCRIPT' named entity 'DISCONTINUOUS' named entity 'THEIR' named entity 'SELECTED' named entity 'BINDING' named entity 'EPITOPE' named entity 'DEVELOPMENT' named entity 'BASIS' named entity 'APPROACH' named entity 'VACCINE' named entity 'USING' named entity 'DRUG RESISTANCE' named entity 'INFECTION' named entity 'MIDDLE EAST RESPIRATORY SYNDROME ' named entity 'FAVORABLE' named entity 'HIGH' named entity 'STUDY' named entity 'ADJUVANTS' named entity 'CONCLUSION' named entity 'ANALYZED' named entity 'HOST CELL' named entity 'IMMUNE RESPONSE' named entity 'ELICIT' named entity 'HIGH EXPRESSION' named entity 'SOUTH KOREA' named entity 'IN SILICO ANALYSIS' named entity 'INDUCING'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software